Last reviewed · How we verify
Anyu Peibo
Anyu Peibo is a Selective serotonin reuptake inhibitor Small molecule drug developed by Shanghai Mental Health Center. It is currently in Phase 3 development for Major depressive disorder. Also known as: Placebo, Anyu Peibo Capsule.
Anyu Peibo is a medication used to treat depression.
Anyu Peibo is being studied as a potential treatment for Major Depressive Disorder (MDD) in a clinical trial. The trial, titled "Safety and Efficacy Study of Anyu Peibo in Treatment of MDD", is comparing the efficacy of Anyu Peibo to a placebo in patients with MDD.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anyu Peibo |
|---|---|
| Also known as | Placebo, Anyu Peibo Capsule |
| Sponsor | Shanghai Mental Health Center |
| Drug class | Selective serotonin reuptake inhibitor |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by modulating the activity of certain neurotransmitters in the brain, such as serotonin and dopamine, to improve mood and reduce symptoms of depression.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
- Comparison of Anyu Peibo With Placebo in Treatment of MDD in China (PHASE3)
- Comparison of Anyu Peibo With Placebo in Treatment of MDD (PHASE2)
- Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anyu Peibo CI brief — competitive landscape report
- Anyu Peibo updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI
Frequently asked questions about Anyu Peibo
What is Anyu Peibo?
How does Anyu Peibo work?
What is Anyu Peibo used for?
Who makes Anyu Peibo?
Is Anyu Peibo also known as anything else?
What drug class is Anyu Peibo in?
What development phase is Anyu Peibo in?
What are the side effects of Anyu Peibo?
What does Anyu Peibo target?
Related
- Drug class: All Selective serotonin reuptake inhibitor drugs
- Target: All drugs targeting Serotonin transporter
- Manufacturer: Shanghai Mental Health Center — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Major depressive disorder
- Also known as: Placebo, Anyu Peibo Capsule
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing